Wikidata

(Q64044885)

English

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

clinical trial

In more languages

Statements

title
A Multicenter, Randomized, Blinded Efficacy and Safety Study of Pasireotide LAR vs Octreotide LAR in Patients With Metastatic Carcinoid Tumors Whose Disease-related Symptoms Are Inadequately Controlled by Somatostatin Analogues. (English)
0 references
sponsor
Novartis
0 references
country
Argentina
0 references
Austria
0 references
Belgium
0 references
Brazil
0 references
Canada
0 references
France
0 references
Germany
0 references
Israel
0 references
Italy
0 references
Norway
0 references
Poland
0 references
Singapore
0 references
Spain
0 references
Sweden
0 references
United Kingdom
0 references
start time
April 2008
0 references
end time
April 2012
0 references
number of participants
186
0 references
research site
Duke Cancer Center
0 references
Novartis
0 references
minimum age
18 year
0 references

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit
                    Retrieved from "https://www.wikidata.org/w/index.php?title=Q64044885&oldid=1857534895"